Rebecca Taub

Rebecca Taub

Company: Madrigal Pharmaceuticals

Job title: Founder & Chief Medical Officer


Phase 3 Development of Resmetirom: A Selective Thyroid Receptor- Beta Agonist for the Treatment of NASH 3:00 pm

Examining the mechanism of action of thyroid receptor beta in the NASH liver Exploring Phase 3 development program for non-cirrhotic NASH Exploring Phase 3 development program for NASH – cirrhosisRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.